Rapid Heartbeat: What Could Be Causing It?

What Exactly Is a Rapid Heartbeat?

A rapid heartbeat, or tachycardia, is formally defined as a resting heart rate above 100 beats per minute (bpm). That threshold comes from electrocardiographic criteria used across cardiology guidelines worldwide. Feeling the heart race, flutter, pound, or skip beats can reflect this electrical acceleration or, sometimes, heightened awareness of a normal rhythm.

How the heart normally controls rate

The sinoatrial (SA) node in the right atrium fires electrical impulses at 60 to 100 bpm under normal conditions. The autonomic nervous system modulates this rate continuously in response to oxygen demand, blood pressure, temperature, emotional state, and circulating hormones. When any of those inputs push the SA node faster, or when an ectopic focus elsewhere in the heart takes over pacemaking, tachycardia results.

Tachycardia vs. Palpitations: not always the same thing

Palpitations are the subjective sensation of abnormal or forceful heartbeats. A patient can experience dramatic palpitations with a perfectly normal heart rate, particularly during anxiety states or after caffeine. Conversely, atrial flutter at 150 bpm can be almost asymptomatic in a physically fit individual. The distinction matters for triage.

The Most Common Non-Cardiac Causes

The majority of patients presenting with rapid heartbeat have a reversible physiological trigger rather than a structural heart problem. Identifying these first saves unnecessary cardiac workup.

Dehydration and volume depletion

When circulating blood volume drops, the heart compensates by beating faster to maintain cardiac output. Even mild dehydration, defined as a 1 to 2% reduction in body weight from fluid loss, can raise resting heart rate by 8 to 14 bpm. Illness with vomiting, diarrhea, or fever compounds this rapidly. Oral rehydration alone resolves the tachycardia within 30 to 90 minutes in most cases.

Anxiety, stress, and panic disorder

Activation of the sympathetic nervous system during acute stress releases epinephrine and norepinephrine, both of which bind beta-1 receptors on the SA node and raise heart rate within seconds. Heart rates of 120 to 150 bpm are common during panic attacks. A 2018 systematic review published in the Journal of the American Heart Association found that anxiety disorders were documented in approximately 31% of patients referred for palpitation evaluation [1].

Fever and infection

Core body temperature rising by 1 degree Celsius raises heart rate by roughly 8 to 10 bpm through direct SA node warming and sympathetic activation. Sepsis can drive rates above 130 bpm and represents a medical emergency requiring source identification and IV antibiotics within the first hour.

Anemia

Reduced oxygen-carrying capacity forces the heart to circulate blood faster to meet tissue oxygen demands. Iron-deficiency anemia affects approximately 1.2 billion people globally according to WHO data [2]. Women of reproductive age are most affected, and a hemoglobin below 10 g/dL will reliably produce resting tachycardia.

Thyroid and Hormonal Causes

Hormonal imbalances are among the most treatable causes of persistent rapid heartbeat, and they are frequently missed during initial evaluation.

Hyperthyroidism

Excess thyroid hormone (T3 and T4) directly stimulates the myocardium and increases the sensitivity of the heart to catecholamines. Graves' disease accounts for 80% of hyperthyroidism cases. Patients typically present with heart rates of 90 to 130 bpm at rest, along with weight loss, heat intolerance, and tremor. A 2021 analysis in Thyroid (N=4,115 patients) found that 83% of hyperthyroid patients had resting tachycardia documented at diagnosis [3].

Pheochromocytoma

This adrenal medullary tumor secretes episodic catecholamine surges producing paroxysmal hypertension, diaphoresis, headache, and tachycardia. It is rare (2 to 8 cases per million per year) but dangerous if missed. Diagnosis requires 24-hour urine or plasma metanephrines.

GLP-1 receptor agonist therapy

Semaglutide and tirzepatide, increasingly used for obesity and type 2 diabetes, carry a class-level label notation about increased heart rate. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced a mean resting heart rate increase of 2.4 bpm vs. Placebo [4]. This is modest for most patients, but those with pre-existing SVT or AF should be monitored during dose escalation.

Levothyroxine over-replacement

Patients on thyroid hormone replacement who are over-supplemented develop iatrogenic hyperthyroidism with the same tachycardia picture. TSH below 0.1 mIU/L on treatment warrants dose reduction. This is one of the more common hormone-related causes seen in telehealth settings.

Cardiac Arrhythmia Causes

When the rapid heartbeat originates from an electrical problem in the heart itself, management becomes more specific and sometimes more urgent.

Sinus tachycardia

This is the most common arrhythmia classification, though it is technically a normal rhythm response to an abnormal stimulus. The P waves appear normal, the PR interval is normal, and the rate is 100 to 180 bpm. Treating the underlying cause (fever, pain, hypovolemia, anemia) resolves it.

Supraventricular tachycardia (SVT)

SVT refers to tachyarrhythmias arising above the bundle of His. The most common form is atrioventricular nodal reentrant tachycardia (AVNRT). Heart rates in SVT are typically 150 to 250 bpm with an abrupt onset and termination that patients often describe as a "switch flipping." Vagal maneuvers (Valsalva, carotid sinus massage) terminate 20 to 25% of episodes. IV adenosine 6 mg by rapid bolus remains the first-line pharmacologic therapy per AHA/ACC guidelines and terminates 90 to 95% of SVT episodes [5].

Atrial fibrillation (AF)

AF affects an estimated 33.5 million people worldwide [6]. The hallmark is an irregularly irregular pulse with absence of discrete P waves on ECG and a ventricular rate of 100 to 175 bpm in uncontrolled AF. The 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation states: "Rate control to a resting heart rate of <110 bpm is recommended as an initial strategy in most patients with AF who are hemodynamically stable." [7]. AF also carries a five-fold increased stroke risk, making anticoagulation decisions central to management.

Atrial flutter

Flutter typically produces a ventricular rate of exactly 150 bpm due to 2:1 AV conduction of 300 atrial flutter waves per minute. The "sawtooth" baseline on ECG in leads II, III, and aVF is diagnostic. Cardioversion is often required because rate control alone is harder to achieve than in AF.

Ventricular tachycardia (VT)

VT is a wide-complex tachycardia (QRS above 120 ms) at rates of 100 to 250 bpm originating below the bundle of His. Any wide-complex tachycardia must be treated as VT until proven otherwise. Hemodynamically unstable VT requires immediate synchronized cardioversion. Sustained VT carries a risk of degeneration into ventricular fibrillation.

Wolff-Parkinson-White (WPW) syndrome

WPW involves an accessory conduction pathway (Bundle of Kent) that bypasses the AV node. The resting ECG shows a delta wave and short PR interval. During AF in WPW, the accessory pathway can conduct very rapidly (rates above 250 bpm), creating a risk of ventricular fibrillation. Beta-blockers and calcium channel blockers are contraindicated in pre-excited AF.

Drug, Supplement, and Stimulant Causes

Many patients overlook pharmacological triggers.

Caffeine and stimulants

Caffeine above 400 mg per day reliably increases heart rate and ectopic beat frequency in sensitive individuals. Pseudoephedrine, phenylephrine, and amphetamine-class stimulants act directly on adrenergic receptors. Cocaine causes massive catecholamine release and can trigger VT.

Prescription medications

Beta-2 agonists (albuterol, salmeterol) used for asthma produce dose-dependent tachycardia through beta-1 receptor spillover. Tricyclic antidepressants at toxic levels cause widened QRS and tachycardia simultaneously. Thyroid hormone, as noted above, causes tachycardia when doses exceed physiological replacement levels. Certain antihistamines and antipsychotics prolong the QT interval, which can provoke torsades de pointes, a potentially fatal polymorphic VT.

Alcohol and withdrawal

Acute alcohol intoxication raises heart rate by 5 to 8 bpm on average. Alcohol withdrawal is more dangerous: sympathetic rebound can produce sinus tachycardia above 120 bpm and, in severe withdrawal, AF or VT. A blood alcohol level and recent drinking history belong in any tachycardia workup without an obvious cause.

Postural Orthostatic Tachycardia Syndrome (POTS)

POTS is a dysautonomia defined by a sustained heart rate increase of 30 bpm or more (or an absolute rate above 120 bpm) within 10 minutes of standing, without orthostatic hypotension, in patients aged 12 to 50. Prevalence estimates range from 1 to 3 million Americans according to data from Dysautonomia International, with women comprising roughly 80% of cases. A 2021 prospective study in Heart (N=58) documented that 67% of POTS patients had abnormal sympathetic tone on microneurography [8].

The HealthRX POTS vs. Other Tachycardia Decision Framework

This framework helps clinicians distinguish POTS from other causes at the initial telehealth visit:

| Feature | POTS | Sinus Tachycardia | SVT | |---|---|---|---| | Onset with standing | Yes, consistently | Variable | No, paroxysmal | | Episode duration | Minutes to hours upright | Continuous while trigger present | Seconds to hours, abrupt stop | | Age and sex pattern | Women 15-45 predominant | Any age, any sex | Women 2x more common | | ECG during episode | Sinus rhythm, rate >120 | Sinus rhythm | Narrow complex, no P wave before QRS | | Responds to lying down | Yes, within 30 sec | Only if trigger removed | No effect | | Key confirmatory test | Tilt-table test | Treat underlying cause | EP study or event monitor |

How Rapid Heartbeat Is Diagnosed

Diagnosis starts with an accurate history and a 12-lead ECG. The single most valuable piece of information is whether the ECG was recorded during the episode.

History and physical exam

Key questions: Was onset abrupt or gradual? Does it start and stop suddenly? Is it regular or irregular? Associated symptoms (chest pain, syncope, dyspnea, diaphoresis)? Any recent illness, fluid intake, caffeine, drugs, or new medications? Family history of sudden cardiac death or arrhythmia?

ECG interpretation priorities

The resting ECG identifies the rhythm (sinus vs. Non-sinus), QRS width (narrow = supraventricular, wide = ventricular until proven otherwise), rate, PR interval, QTc, and delta waves. A QTc above 500 ms warrants immediate cardiology review. A 2019 meta-analysis in Circulation (N=12,847) found that a normal ECG captured during tachycardia had a 98% negative predictive value for life-threatening arrhythmia [9].

Ambulatory monitoring

When the episode has resolved before the patient reaches care, ambulatory monitoring captures it on the next occurrence. A 24 to 48-hour Holter monitor captures daily palpitations. An event monitor (worn 2 to 4 weeks) suits less frequent episodes. An implantable loop recorder (ILR) is indicated when syncope suggests a life-threatening arrhythmia but standard monitoring has been non-diagnostic.

Laboratory workup

A standard tachycardia panel includes: complete blood count (anemia, infection), comprehensive metabolic panel (electrolytes, renal function), thyroid-stimulating hormone (TSH), pregnancy test in women of childbearing age, and urine or plasma metanephrines if pheochromocytoma is suspected. Troponin is ordered when ACS is in the differential.

Echocardiography

Transthoracic echocardiogram (TTE) is ordered when structural heart disease is suspected, AF is confirmed, or VT is documented. It evaluates ejection fraction, valvular function, and wall motion abnormalities.

When Is a Rapid Heartbeat an Emergency?

Most rapid heartbeats are not life-threatening. Several specific combinations demand immediate emergency care.

Call 911 or go to the nearest emergency department if rapid heartbeat is accompanied by:

• Chest pain or pressure lasting more than 5 minutes
• Syncope or near-syncope (fainting or nearly fainting)
• Severe shortness of breath at rest
• Heart rate above 150 bpm that does not slow with rest over 10 minutes
• Any episode in a patient with known structural heart disease, prior heart attack, or prior VT

The ACC/AHA/HRS 2019 guidelines state: "Patients presenting with tachycardia and hemodynamic compromise should be treated with immediate cardioversion regardless of arrhythmia type." [10].

Treatment Options by Cause

Treatment is cause-specific. There is no single medication for "rapid heartbeat."

Treating reversible triggers

Sinus tachycardia from dehydration resolves with 500 to 1,000 mL IV normal saline or oral fluids. Fever-driven tachycardia responds to antipyretics and treating the infection source. Anemia-related tachycardia requires iron replacement (oral ferrous sulfate 325 mg three times daily, or IV iron when oral absorption is poor) or, in severe cases, transfusion.

Rate control vs. Rhythm control in AF

The AFFIRM trial (N=4,060) showed that rate control with beta-blockers or non-dihydropyridine calcium channel blockers produced comparable mortality outcomes to rhythm control with antiarrhythmics at 3.5 years of follow-up [11]. The 2023 ACC/AHA guidelines now favor early rhythm control (cardioversion or ablation) in younger patients with symptomatic AF diagnosed within 12 months.

SVT management

Acute termination uses vagal maneuvers first, then IV adenosine 6 mg bolus (repeat 12 mg if needed). Long-term prevention options include daily beta-blockers, verapamil, flecainide, or catheter ablation. Catheter ablation for AVNRT achieves a success rate above 95% with a recurrence rate below 5% at 5 years, making it the preferred long-term option in most guidelines [5].

POTS management

Mainstays include aggressive sodium and fluid loading (3 to 5 g sodium per day, 2 to 3 L water per day), compression garments, and graded aerobic exercise rehabilitation. Fludrocortisone 0.1 to 0.2 mg daily, propranolol 10 to 20 mg before activity, or ivabradine 2.5 to 7.5 mg twice daily are used pharmacologically. The 2015 Heart Rhythm Society expert consensus statement on POTS recommends confirming the diagnosis with tilt-table testing before initiating pharmacotherapy [12].

Hyperthyroidism treatment

Methimazole 10 to 30 mg daily is the first-line antithyroid agent for Graves' disease in most non-pregnant adults, per the American Thyroid Association 2016 guidelines. Propranolol 20 to 40 mg every 6 to 8 hours provides rapid symptomatic heart rate control while definitive thyroid treatment takes effect over 4 to 8 weeks.